Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 5/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010505 | 1.00 | BTK (0.42) | BTKGPR119CCNT1CDK9MGLL | |
| SCHEMBL22010771 | 0.91 | GPR119 (0.48) | BTKGPR119CCNT1CDK9EGLN2 | |
| SCHEMBL22010769 | 0.91 | GPR119 (0.48) | BTKGPR119CCNT1CDK9EGLN2 | |
| SCHEMBL22010912 | 0.87 | BTK (0.44) | BTKGPR119CCNT1CDK9BACE1 | |
| SCHEMBL22011041 | 0.87 | BTK (0.44) | BTKGPR119CCNT1CDK9BACE1 | |
| SCHEMBL30161685 | 0.86 | BTK (0.52) | BTKGPR119CCNT1CDK9 | |
| SCHEMBL22010906 | 0.86 | BTK (0.52) | BTKGPR119CCNT1CDK9 | |
| SCHEMBL22011512 | 0.84 | CCNT1 (0.43) | BTKGPR119CCNT1CDK9 | |
| SCHEMBL22010768 | 0.84 | CCNT1 (0.43) | BTKGPR119CCNT1CDK9 | |
| SCHEMBL22010468 | 0.81 | BTK (0.47) | BTKGPR119CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | BTK 1478/4885GPR119 4033/4885CCNT1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.